Mavelertinib
N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide
Molecular Identity
Mavelertinib
N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide
PubChem CID: 91668194
2D Structure
Properties
C18H22FN9O2
Molecular Formula
415.40
Molecular Weight
g/mol
415.1880
Exact Mass
Da
1.2
XLogP
Drug-like (Lipinski: < 5)
115
TPSA
Good oral absorption (< 140 A²)
2
H-Bond Donors
9
H-Bond Acceptors
643
Complexity
SMILES
Canonical SMILES
SMILES: CN1C=C(C(=N1)OC)NC2=C3C(=NC(=N2)N4CC(C(C4)F)NC(=O)C=C)N(C=N3)CIsomeric SMILES
SMILES: CN1C=C(C(=N1)OC)NC2=C3C(=NC(=N2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)N(C=N3)CSynonyms(20)
Mavelertinib1776112-90-3PF-06747775Mavelertinib [USAN]YXX2180047Egfr T790M inhibitor PF-06747775PF06747775MAVELERTINIB [INN]MAVELERTINIB [WHO-DD]N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide2-Propenamide, N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)-3-pyrrolidinyl)-compound 21 [PMID: 28287730]2-Propenamide, N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl]-3-pyrrolidinyl]-compound 21 (PMID: 28287730)N-((3R,4R)-4-FLUORO-1-(6-((3-METHOXY-1-METHYL-PYRAZOL-4-YL)AMINO)-9-METHYL-PURIN-2-YL)PYRROLIDIN-3-YL)PROP-2-ENAMIDE
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to Mavelertinib
Loading drug network...